

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'HCAPLUS' AT 08:46:27 ON 27 APR 2006
FILE 'HCAPLUS' ENTERED AT 08:46:27 ON 27 APR 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	89.35	423.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.00	-12.00

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	91.88	425.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.00	-12.00

FILE 'REGISTRY' ENTERED AT 08:46:47 ON 27 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS


for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10511155amend1.str



chain nodes :

10 11 12

ring nodes :

1 2 3 4 5 6 7 8 9 14 15 16 17 18 19 20 21 22

chain bonds :

10-11 11-12 12-14

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 14-15 14-19 15-16 16-17 16-20
17-18 17-22 18-19 20-21 21-22

exact/norm bonds :

2-3 2-7 3-9 7-8 8-9 11-12 12-14 16-20 17-22 20-21 21-22

exact bonds :

10-11

normalized bonds :

1-2 1-6 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 25:CLASS

Generic attributes :

12:

Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :


Node 12: Limited

C,C4

N,N2

L12 STRUCTURE UPLOADED

=> d 112
L12 HAS NO ANSWERS
L12 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 112
SAMPLE SEARCH INITIATED 08:47:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12907 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 251334 TO 264946
PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L12

=> s 112 full
FULL SEARCH INITIATED 08:47:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 255970 TO ITERATE

100.0% PROCESSED 255970 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.04

L14 4 SEA SSS FUL L12

=> fil hcaplus			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	166.94	592.91	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
	ENTRY	SESSION	
CA SUBSCRIBER PRICE	0.00	-12.00	

FILE 'HCAPLUS' ENTERED AT 08:47:25 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.


=> s l14
L15 1 L14

=> d ed abs ibib hitstr

L15 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 24 Oct 2003
 GI



II



III

AB Title compds. I [R1 = H, A, SO2A; A = alkyl, alkoxyalkyl; D-E = R2C=CR4, R2R3-CR4R5; R2, R3, R4, R5 = H, A, cycloalkyl, etc.; X1 = (CHR7), (CHR7)h-Q-(CHR8)k; Q = O, S, NR6, etc.; R6 = H, A, cycloalkyl; R7, R8, R12 = definition as given for R2-R5; g = 1-6; h, k = 0-6; p = 0-3; E = H, A, cycloalkyl, etc.; G = (un)substituted alkylene; E and G together form (un)substituted mono or bicyclic heterocycle; X2 = definition as given for X1; Z = H, (un)substituted aromatic carbocycle] and their pharmaceutically acceptable salts and formulations were prepared. For example, N-alkylation of 4-(4-fluorobenzyl)piperideine with methanesulfonic ester II, e.g., prepared from indole-4-carboxylic acid Me ester in 7-steps, afforded the hydrochloride salt of indole-3-carbonitrile III after work-up. Compds. I are claimed useful as excitatory amino acid antagonists (no data provided) and as 5-HT reuptake inhibitors.

ACCESSION NUMBER: 2003183703 HCPLUS

DOCUMENT NUMBER: 139:337888

TITLE: Preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases

INVENTOR(S): Schadt, Oliver; Boettcher, Henning; Leibrock, Joachim; Schiemann, Kai; Heinrich, Timo; Hoelzemann, Guenter; Van Amsterdam, Christoph; Bartoszyk, Gerdi; Seyfried, Christoph

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----


L15 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 615569-41-0 HCPLUS
 CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-5-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-77-2 HCPLUS
 CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-5-yl)propyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L15 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ED 2003087086 A2 20031023 WO 2003-EP3806 20030411
 GI 2003087086 A3 20040722
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TO, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, HL, MR, NE, SN, TO, TG
 DE 10217006 A1 20031106 DE 2002-10217006 20020416
 CA 2482655 AA 20031023 CA 2003-2482655 20030411
 AU 2003224064 A1 20031027 AU 2003-224064 20030411
 EP 1497279 A2 20050119 EP 2003-720455 20030411
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, RU, SK
 US 2005153980 A1 20050714 US 2003-511155 20030411
 JP 2005523310 T2 20050804 JP 2003-584042 20030411
 PRIORITY APPLN. INFO.: DE 2002-10217006 A 20020416
 WO 2003-EP3806 W 20030411


OTHER SOURCE(S): MARPAT 139:337888

IT 615569-38-5P 615569-40-9P 615569-41-0P

615569-77-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 615569-38-5 HCPLUS
 CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-6-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-40-9 HCPLUS
 CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-6-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

=> fil reg			
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION	
FULL ESTIMATED COST	7.64	600.55	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION	
CA SUBSCRIBER PRICE	-0.75	-12.75	

FILE 'REGISTRY' ENTERED AT 08:48:12 ON 27 APR 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
 DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
 Uploading C:\Program Files\Stnexp\Queries\10511155amend2.str



```

chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :

```

10511155amend

10-11 11-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS

Generic attributes :

12:

Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :


Node 12: Limited

C,C4

N,N2

L16 STRUCTURE UPLOADED

=> d 116
L16 HAS NO ANSWERS
L16 STR



Structure attributes must be viewed using STN Express query preparation.


=> s 116
SAMPLE SEARCH INITIATED 08:49:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 134667 TO ITERATE

1.58 PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2671670 TO 2715010
PROJECTED ANSWERS: 0 TO 0

L17 0 SEA SSS SAM L16

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend3.str



chain nodes :

10 11 12

ring nodes :

1 2 3 4 5 6 7 8 9 17 18 19 20 21 22

chain bonds :

10-11 11-12 12-17

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 17-18 17-22 18-19 19-20 20-21
21-22

exact/norm bonds :

2-3 2-7 3-9 7-8 8-9 11-12 12-17

exact bonds :

10-11

normalized bonds :

1-2 1-6 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom

Generic attributes :

12:

Saturation : Saturated
 Number of Carbon Atoms : less than 7
 Type of Ring System : Monocyclic

Element Count :

Node 12: Limited

C,C4


N,N2

L18 STRUCTURE UPLOADED

=> d 118

L18 HAS NO ANSWERS


L18 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10511155amend4.str



chain nodes :

10 11 12 17

ring nodes :

1 2 3 4 5 6 7 8 9 18 19 20 21 22 23

chain bonds :

10-11 11-12 12-17 17-18

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 18-19 18-23 19-20 20-21 21-22
22-23

exact/norm bonds :

2-3 2-7 3-9 7-8 8-9 11-12 12-17 17-18

exact bonds :

10-11

normalized bonds :

1-2 1-6 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23

G1:CH₂,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom

Generic attributes :

12:

Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :


Node 12: Limited

C,C4

N,N2

L19 STRUCTURE UPLOADED

=> d 119
 L19 HAS NO ANSWERS
 L19 STR

G1 CH₂, O

Structure attributes must be viewed using STN Express query preparation.

=> s 118
 SAMPLE SEARCH INITIATED 08:54:42 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 85537 TO ITERATE

2.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**
 PROJECTED ITERATIONS: 1693368 TO 1728112
 PROJECTED ANSWERS: 0 TO 0

L20 0 SEA SSS SAM L18

=> s 119
 SAMPLE SEARCH INITIATED 08:54:48 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 78632 TO ITERATE

2.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**
 PROJECTED ITERATIONS: 1555970 TO 1589310
 PROJECTED ANSWERS: 0 TO 0

L21 0 SEA SSS SAM L19

=> fil hcaplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION

FULL ESTIMATED COST	5.28	605.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.75

FILE 'HCAPLUS' ENTERED AT 08:55:26 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s us20050153980/pn
L22 1 US20050153980/PN
(US2005153980/PN)

=> d 122

L22 ANSWER 1 OF 1 HCAPIUS COPYRIGHT 2006 ACS on STN
 AN 2003:837073 HCAPIUS
 DN 139:337888
 TI Preparation of indole-3-carbonitriles as excitatory amino acid antagonists
 for the treatment of neurodegenerative diseases
 IN Schadt, Oliver; Boettcher, Henning; Leibrock, Joachim; Schiemann, Kai;
 Heinrich, Timo; Hoelzemann, Guenter; Van Amsterdam, Christoph; Bartoszyk,
 Gerdi; Seyfried, Christoph
 PA Merck Patent G.m.b.H., Germany
 SO PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087086	A2	20031023	WO 2003-EP3806	20030411
PI WO 2003087086	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GR, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, RU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10217006	A1	20031106	DE 2002-10217006	20020416
CA 2482655	AA	20031023	CA 2003-2482655	20030411
AU 2003224064	A1	20031027	AU 2003-224064	20030411
EP 1497279	A2	20050119	EP 2003-720455	20030411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005153980	A1	20050714	US 2003-511155	20030411 <--
JP 2005523310	T2	20050804	JP 2003-584042	20030411
PRAI DE 2002-10217006	A	20020416		
WO 2003-EP3806	W	20030411		
OS MARPAT 139:337888				

```
=> select 122 1 rn  
E1 THROUGH E66 ASSIGNED
```

FILE 'REGISTRY' ENTERED AT 08:56:49 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005. A new display format, IDERL, is now
* available and contains the CA role and document type information.
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s e1-e66

1 1074-85-7/BI
(1074-85-7/RN)
1 1074-86-8/BI
(1074-86-8/RN)
1 124-63-0/BI
(124-63-0/RN)
1 183288-46-2/BI
(183288-46-2/RN)
1 39830-66-5/BI
(39830-66-5/RN)


1 615569-28-3/BI
(615569-28-3/RN)
1 615569-29-4/BI
(615569-29-4/RN)
1 615569-30-7/BI
(615569-30-7/RN)
1 615569-31-8/BI
(615569-31-8/RN)
1 615569-32-9/BI
(615569-32-9/RN)
1 615569-33-0/BI
(615569-33-0/RN)
1 615569-34-1/BI
(615569-34-1/RN)
1 615569-35-2/BI
(615569-35-2/RN)
1 615569-36-3/BI
(615569-36-3/RN)
1 615569-37-4/BI
(615569-37-4/RN)
1 615569-38-5/BI
(615569-38-5/RN)
1 615569-39-6/BI
(615569-39-6/RN)
1 615569-40-9/BI
(615569-40-9/RN)
1 615569-41-0/BI
(615569-41-0/RN)
1 615569-42-1/BI
(615569-42-1/RN)
1 615569-43-2/BI
(615569-43-2/RN)
1 615569-44-3/BI
(615569-44-3/RN)
1 615569-45-4/BI
(615569-45-4/RN)
1 615569-46-5/BI
(615569-46-5/RN)
1 615569-47-6/BI
(615569-47-6/RN)
1 615569-48-7/BI
(615569-48-7/RN)
1 615569-49-8/BI
(615569-49-8/RN)
1 615569-50-1/BI
(615569-50-1/RN)
1 615569-51-2/BI
(615569-51-2/RN)
1 615569-52-3/BI
(615569-52-3/RN)
1 615569-53-4/BI
(615569-53-4/RN)
1 615569-54-5/BI
(615569-54-5/RN)
1 615569-55-6/BI
(615569-55-6/RN)
1 615569-56-7/BI
(615569-56-7/RN)
1 615569-57-8/BI
(615569-57-8/RN)

1 615569-58-9/BI
(615569-58-9/RN)
1 615569-59-0/BI
(615569-59-0/RN)
1 615569-60-3/BI
(615569-60-3/RN)
1 615569-61-4/BI
(615569-61-4/RN)
1 615569-62-5/BI
(615569-62-5/RN)
1 615569-63-6/BI
(615569-63-6/RN)
1 615569-64-7/BI
(615569-64-7/RN)
1 615569-65-8/BI
(615569-65-8/RN)
1 615569-66-9/BI
(615569-66-9/RN)
1 615569-67-0/BI
(615569-67-0/RN)
1 615569-68-1/BI
(615569-68-1/RN)
1 615569-69-2/BI
(615569-69-2/RN)
1 615569-70-5/BI
(615569-70-5/RN)
1 615569-71-6/BI
(615569-71-6/RN)
1 615569-72-7/BI
(615569-72-7/RN)
1 615569-73-8/BI
(615569-73-8/RN)
1 615569-74-9/BI
(615569-74-9/RN)
1 615569-75-0/BI
(615569-75-0/RN)
1 615569-76-1/BI
(615569-76-1/RN)
1 615569-77-2/BI
(615569-77-2/RN)
1 615569-78-3/BI
(615569-78-3/RN)
1 615569-79-4/BI
(615569-79-4/RN)
1 615569-80-7/BI
(615569-80-7/RN)
1 615569-81-8/BI
(615569-81-8/RN)
1 615569-82-9/BI
(615569-82-9/RN)
1 615569-83-0/BI
(615569-83-0/RN)
1 615569-84-1/BI
(615569-84-1/RN)
1 615569-86-3/BI
(615569-86-3/RN)
1 79-20-9/BI
(79-20-9/RN)
1 88089-29-6/BI
(88089-29-6/RN)

1 92822-02-1/BI
(92822-02-1/RN)
L23 66 (1074-85-7/BI OR 1074-86-8/BI OR 124-63-0/BI OR 183288-46-2/BI
OR 39830-66-5/BI OR 615569-28-3/BI OR 615569-29-4/BI OR 615569-3
0-7/BI OR 615569-31-8/BI OR 615569-32-9/BI OR 615569-33-0/BI OR
615569-34-1/BI OR 615569-35-2/BI OR 615569-36-3/BI OR 615569-37-4
/BI OR 615569-38-5/BI OR 615569-39-6/BI OR 615569-40-9/BI OR
615569-41-0/BI OR 615569-42-1/BI OR 615569-43-2/BI OR 615569-44-3
/BI OR 615569-45-4/BI OR 615569-46-5/BI OR 615569-47-6/BI OR
615569-48-7/BI OR 615569-49-8/BI OR 615569-50-1/BI OR 615569-51-2
/BI OR 615569-52-3/BI OR 615569-53-4/BI OR 615569-54-5/BI OR
615569-55-6/BI OR 615569-56-7/BI OR 615569-57-8/BI OR 615569-58-9
/BI OR 615569-59-0/BI OR 615569-60-3/BI OR 615569-61-4/BI OR
615569-62-5/BI OR 615569-63-6/BI OR 615569-64-7/BI OR 615569-65-8
/BI OR 615569-66-9/BI OR 615569-67-0/BI OR 615569-68-1/BI OR
615569-69-2/BI OR 615569-70-5/BI OR 615569-71-6/BI OR 615569-72-7
/BI OR 615569-73-8/BI OR 615569-74-9/BI OR 615569-75-0/BI OR
615569-76-1/BI OR 615569-77-2/BI OR 615569

=> d 123 1-66


L23 ANSWER 1 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-86-3 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[(methylsulfonyl)oxy]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 2 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-84-1 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[(methylsulfonyl)oxy]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 3 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-83-0 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H12 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 4 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-82-9 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-4-propanoic acid, 3-cyano-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H12 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 5 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-81-8 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Propenoic acid, 3-(3-cyano-1H-indol-4-yl)-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H10 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 6 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-80-7 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-{4-[(4-fluorophenoxy)cyclohexyl]propyl}- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 7 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-79-4 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-{4-[(2,4-difluorophenyl)methyl]cyclohexyl}propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H26 F2 N2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 8 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-78-3 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-{4-[(4-fluorophenyl)methyl]cyclohexyl}propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H27 F N2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 9 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-77-2 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C25 H25 N5 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (615569-41-0)



● HCl


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 10 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-76-1 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C24 H26 F N3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (615569-31-8)




● HCl
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 11 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-78-0 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1-Piperazinecarbothioamide, 4-[3-(3-cyano-1H-indol-5-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H21 N5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 12 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-74-9 REGISTRY
ED Entered STN: 12 Nov 2003
CN 4-Thiazolecarboxamide, 2-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H22 N6 O S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 13 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-73-B REGISTRY
ED Entered STN: 12 Nov 2003
CN Carbamic acid, [6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H27 N5 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 14 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-72-7 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(3-amino-2-oxo-2H-1-benzopyran-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 15 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-71-6 REGISTRY
ED Entered STN: 12 Nov 2003
CN Carbamic acid, [6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H29 N5 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 16 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-70-5 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[3-(2-oxo-1-pyrrolidinyl)propyl]amino]propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H24 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 17 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-69-2 REGISTRY
ED Entered STN: 12 Nov 2003
CN 4-Thiazolecarboxylic acid, 2-[4-[(3-(3-cyano-1H-indol-5-yl)propyl)-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H25 N5 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 18 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-68-1 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[(4-[(3-pyridinyl)-2-thiazolyl]-1-piperazinyl]propyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 N6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 19 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-67-0 REGISTRY
ED Entered STN: 12 Nov 2003
CN Acetamide, N-[4-[(1-[3-(3-cyano-1H-indol-5-yl)propyl)-4-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H30 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 20 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-66-9 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[(4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]propyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H25 N7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 21 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-65-B REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-{4-(3-methoxyphenyl)-3-methyl-1-piperazinyl}propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H28 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 22 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-64-7 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-{[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino}propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H21 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 23 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-63-6 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-{4-(2-pyrimidinyl)-1-piperazinyl}propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H22 N6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 24 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-62-5 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-{4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-piperazinyl}propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 25 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-61-4 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[(3-[(3-pyridinylmethyl)amino]propyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 26 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-60-3 REGISTRY
ED Entered STN: 12 Nov 2003
CN Acetamide, N-[6-[(4-[(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H27 NS O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 27 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-59-0 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[(3-[(4-(1H-pyrazol-1-ylmethyl)-1-piperidinyl)propyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H25 NS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 28 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-58-9 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[(3-[(4-(4-cyano-2-methoxyphenyl)-1-piperazinyl)propyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 NS O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 29 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-57-8 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(4-cyano-3-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 NS O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 30 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-56-7 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(2-cyano-3-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 NS O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 31 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-55-6 REGISTRY
ED Entered STN: 12 Nov 2003
CN Benzamide, 4-[[1-[3-(3-cyano-1H-indol-6-yl)propyl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 32 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-54-5 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 NS S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 33 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-53-4 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(4-fluoro-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 F N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 34 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-52-3 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 F N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 35 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-51-2 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H25 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 36 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-50-1 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 F N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 37 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 615569-49-8 REGISTRY
 ED Entered STN: 12 Nov 2003
 CN 1H-Indole-3-carbonitrile, 5-[3-{4-(1H-indol-1-yl)-1-piperidinyl}propyl]-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H26 N4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 38 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 615569-49-7 REGISTRY
 ED Entered STN: 12 Nov 2003
 CN 1H-Indole-3-carbonitrile, 1-(methylsulfonyl)-5-[3-{3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl}- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H29 N5 O3 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 39 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 615569-47-6 REGISTRY
 ED Entered STN: 12 Nov 2003
 CN 1H-Indole-3-carbonitrile, 5-[3-{4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl}propyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H26 N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 40 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 615569-46-5 REGISTRY
 ED Entered STN: 12 Nov 2003
 CN 1H-Indole-3-carbonitrile, 5-[3-{4-(8-quinolinyl)-1-piperazinyl}propyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H25 NS
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 41 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-45-4 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-5-carbonamide, 3-[1-[3-(3-cyano-1H-indol-5-yl)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H27 N5 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 42 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-44-3 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,1,3-benzothiadiazol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H22 N6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 43 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-43-2 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H27 N5 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 44 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-42-1 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1H-indol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 45 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-41-0 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-5-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 46 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-40-9 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-4-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 47 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-39-6 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2-oxo-2H-1-benzopyran-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H24 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 48 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-30-5 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-6-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 49 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-37-4 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(4-cyanophenyl)-1-piperazinyl]propyl]-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 50 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-36-3 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(4-fluorophenoxy)-1-piperidinyl]propyl]-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H24 F N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 51 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-35-2 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 F N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 52 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-34-1 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-[(2,4-difluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F2 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 53 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-33-0 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-(4-fluorophenoxy)-1-piperidinyl]propyl]-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H24 F N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 54 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-32-9 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-[(2,4-difluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F2 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 55 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-31-8 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 F N3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 56 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-30-7 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(4-fluorophenoxy)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H24 F N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 57 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-29-4 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-[(2,4-difluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F2 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 58 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-29-3 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 F N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 59 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 183288-46-2 REGISTRY
ED Entered STN: 22 Nov 1996
CN 2-Benzofuran-2-carboxamide, 5-(1-piperazinyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(1-Piperazinyl)benzofuran-2-carboxamide
CN 5-(piperazin-1-yl)benzofuran-2-carboxamide
FS 3D CONCORD
MF C13 H15 N3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 60 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 92822-02-1 REGISTRY
ED Entered STN: 17 Dec 1984
CN Piperidine, 4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(4-Fluorobenzyl)piperidine
CN 4-(p-Fluorobenzyl)piperidine
CN 4-[(4-Fluorophenyl)methyl]piperidine
FS 3D CONCORD
MF C12 H16 F N
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CSChem, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
61 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L23 ANSWER 61 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 68089-29-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2-Propenoic acid, 3-(1H-indol-4-yl)-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H11 N O2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 62 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 39830-66-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole-4-carboxylic acid, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole-4-carboxylic acid, methyl ester (6CI)
OTHER NAMES:
CN 4-Methoxycarbonylindole
CN Methyl 1H-indole-4-carboxylate
CN Methyl 4-indolecarboxylate
FS 3D CONCORD
MF C10 H9 N O2
CL COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

91 REFERENCES IN FILE CA (1907 TO DATE)
91 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L23 ANSWER 63 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 1074-86-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole-4-carboxaldehyde (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole-4-carboxaldehyde (7CI, 8CI)
OTHER NAMES:
CN 4-Formylindole
CN 4-Indolecarbaldehyde
CN NSC 337264
FS 3D CONCORD
MF C9 H7 N O
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHM, IFICDB, IFIPAT, IFIUDB, NAPRALERT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

80 REFERENCES IN FILE CA (1907 TO DATE)
80 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L23 ANSWER 64 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 1074-85-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole-4-methanol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole-4-methanol (7CI, 8CI)
FS 3D CONCORD
MF C9 H9 N O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHM, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L23 ANSWER 65 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 124-03-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Chloro methyl sulfone
 CN Mesyl chloride
 CN Methanesulfonic acid chloride
 CN Methanesulphonyl chloride
 CN Methyl sulfochloride
 CN Methylsulfonyl chloride
 CN NSC 15039
 FS 3D CONCORD
 MF C H3 Cl O2 S
 CI COM
 LC STM Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
 CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMX, CHEMIST, CIN, CSChem,
 DETHERM*, DIPPR, EMBASE, GMELIN, HSDB*, IFICDB, IFIPAT, IFIUDB,
 MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, PS, RTECS*, SPECINFO,
 SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL*, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



L23 ANSWER 66 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 79-20-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Acetic acid, methyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Devoton
 CN Methyl acetate
 CN Methyl ethanate
 CN NSC 405071
 CN Tereton
 FS 3D CONCORD
 MF C3 H6 O2
 CI COM
 LC STM Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
 CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMX, CHEMIST,
 CHEMSAFE, CIN, CSChem, CSNB, DDFU, DETHERM*, DIPPR*, DRUGU, EMBASE,
 ENCOMPAT, ENCOMPAT2, ENCOMPAT, ENCOMPAT2, GMELIN*, HSDB*, IFICDB,
 IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC,
 PDLCOM*, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA,
 ULIDAT, USPAT2, USPATFULL, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5201 REFERENCES IN FILE CA (1907 TO DATE)
 47 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 5225 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 39 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

8622 REFERENCES IN FILE CA (1907 TO DATE)
 32 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 8640 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 200 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> log h		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.28	738.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.75

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:58:04 ON 27 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:03:28 ON 27 APR 2006

FILE 'REGISTRY' ENTERED AT 12:03:33 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The G1 marker and document type information have been removed.



* the IDE display format and the 21 field has been added,
* effective March 20, 2005. A new display format, IDERL, is now
* available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend5.str



chain nodes :

10511155amend

```
10 11 12 18
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
10-11 11-12 12-18
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12 12-18
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6
```

G1:CH2,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 18:Atom

Generic attributes :

12:

Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

18:

Saturation : Unsaturated

Element Count :

Node 12: Limited

C,C4

N,N2

Node 18: Limited


C,C4-9

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 CH2,O

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 12:03:51 FILE 'REGISTRY'

10511155amend

SAMPLE SCREEN SEARCH COMPLETED - 134667 TO ITERATE


1.5% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2671670 TO 2715010
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend7.str



chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9 12 18 19 20 21 22
chain bonds :
10-11 11-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 12-18 12-22 18-19 19-20 20-21
21-22
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12 12-18 12-22 18-19 19-20 20-21 21-22
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6

G1:CH2,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
Element Count :
Node 12: Limited
C,C4
N,N2

Node 18: Limited
C,C4
N,N2

Node 19: Limited
C,C4
N,N2

Node 20: Limited
C,C4

10511155amend


N,N2

Node 21: Limited
C,C4
N,N2

Node 22: Limited
C,C4
N,N2

L3 STRUCTURE UPLOADED

=> d 13
L3 HAS NO ANSWERS
L3 STR



G1 CH₂,O

Structure attributes must be viewed using STN Express query preparation.

=> s 13
SAMPLE SEARCH INITIATED 12:06:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12901 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 251216 TO 264824
PROJECTED ANSWERS: 124 TO 650

L4 3 SEA SSS SAM L3

=> s 13 full
FULL SEARCH INITIATED 12:06:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 257553 TO ITERATE

100.0% PROCESSED 257553 ITERATIONS 504 ANSWERS
SEARCH TIME: 00.00.03

L5 504 SEA SSS FUL L3

=> fil hcaplus

10511155amend

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.70	168.91

FILE 'HCAPLUS' ENTERED AT 12:06:43 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15

L6 553 L5

=> d ed abs ibib hitstr 550-553

L6 ANSWER 550 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Six oxindoles I ($\text{RRIN} = \text{Me}_2\text{CHNH}_2$, morpholino, piperidino, 4-methylpiperazino, etc.; $\text{R2} = \text{H, Me, Et, CHMe}_2, \text{Bu}$; $\text{R3} = \text{H, Me, PhCH}_2$, cyclohexyl, etc.; $\text{R4, R5} = \text{H, Me}$), having β -adrenergic, antiallergic and other activities (no data), were prepared by reducing their 4-alkynoyl analogs, e.g. II. Thus, 7.6 g 3,3-dimethyl-7-methoxyindole and 16 g AlCl₃ in dichloroethane heated with 23 g BrCH₂COBr at 50–60° 1.5 h gave 6.2 g 4-(2-bromobutyryl)-3,3-dimethyl-7-methoxyindole, which (5 g) was refluxed with Me₂NNH₂ to give 6 g II. HBr ($\text{R3} = \text{Me}$). Similarly prepared was II.HBr ($\text{R3} = \text{H}$), which (1.1 g) was reduced with NaBH₄ in aqueous MeOH at pH 7.5–8.0 to give 430 mg I.HCl.

ACCESSION NUMBER: 1978:24145 HCAPLUS

DOCUMENT NUMBER: 89:24145

TITLE: 4-(1-Hydroxy-2-aminoalkyl)oxindoles

INVENTOR(S): Yoshizaki, Shiro; Sato, Tadao; Nakagawa, Kazuyuki

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53018562	A2	19780220	JP 1976-92150	19760802
JP 59019537	B4	19840507		
PRIORITY APPLN. INFO.:			JP 1976-92150	A 19760802
IT 66931-26-8P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				
RN 66931-26-8 HCAPLUS				
CN 2H-Indol-2-one, 1,3-dihydro-4-[1-hydroxy-2-(4-methyl-1-piperazinyl)propyl]-3,3-dimethyl-7-(phenylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)				

L6 ANSWER 550 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

L6 ANSWER 551 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Twenty title derivs. I ($\text{R, R1, R2, R3, R4} = \text{H, alkyl; R5, R6} = \text{H, alkyl, aralkyl, phenoxyalkyl; R5R6 may form a heterocyclic ring}$) and their acid salts were prepared by reaction of II ($\text{X} = \text{halo}$) with R5R6NH. I had vasodilating and platelet aggregation inhibitory activities (no data). Thus, a mixture of 5 g PhOCH₂CHMeNH₂ and 5 g II ($\text{R} = \text{R1} = \text{R3} = \text{H, R2} = \text{R4} = \text{Me, X} = \text{Br}$) in MeCN was refluxed 5 h to give 2.73 g I.HCl ($\text{R} = \text{R1} = \text{R3} = \text{H, R2} = \text{R4} = \text{Me, R6} = \text{PhOCH}_2\text{CHMe}$).

ACCESSION NUMBER: 1978:62293 HCAPLUS

DOCUMENT NUMBER: 88:62293

TITLE: α -Substituted aminoalkanoyloxindole derivatives

INVENTOR(S): Nishi, Takeo; Oshiro, Yasuo; Nakagawa, Kazuyuki

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52118464	A2	19771004	JP 1976-36280	19760331
JP 58040539	B4	19830906		
PRIORITY APPLN. INFO.:			JP 1976-36280	A 19760331
IT 65435-49-6P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				
RN 65435-49-6 HCAPLUS				
CN 2H-Indol-2-one, 1,3-dihydro-3-methyl-5-(1-oxo-2-(1-piperazinyl)propyl)-2H-Indol-2-one, 1,3-dihydro-5-(1-hydroxy-2-(1-piperazinyl)propyl)-3-methyl-, dihydrochloride (9CI) (CA INDEX NAME)				



L6 ANSWER 552 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Fifteen vasodilators I, ($\text{R, R1, R2, R3, R4} = \text{H, alkyl; R5, R6} = \text{H, alkyl, aralkyl, phenoxyalkyl; R5R6 may form a heterocyclic ring; Z} = \text{H}_2\text{OH}$) and their acid salts were prepared by reduction of I ($\text{Z} = \text{O}$). Thus, a mixture of 2.5 g II.HCl ($\text{R} = \text{R1} = \text{R3} = \text{H, R2} = \text{R4} = \text{Me, R6} = \text{PhOCH}_2\text{CHMe}$) was hydrogenated at 1 kg/cm² over 0.2 g PtO₂ in EtOH 8 h at room temperature to give

24.6% I.HCl ($\text{R} = \text{R1} = \text{R3} = \text{R5} = \text{H, R2} = \text{R4} = \text{Me, R6} = \text{PhOCH}_2\text{CHMe}; \text{Z} = \text{H}_2\text{OH}$).

ACCESSION NUMBER: 1978:62292 HCAPLUS

DOCUMENT NUMBER: 88:62292

TITLE: Oxindole derivatives

INVENTOR(S): Nishi, Takeo; Oshiro, Yasuo; Nakagawa, Kazuyuki

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52118465	A2	19771004	JP 1976-36281	19760331
JP 58025673	B4	19830528		
PRIORITY APPLN. INFO.:			JP 1976-36281	A 19760331
IT 65434-99-3P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				
RN 65434-99-3 HCAPLUS				
CN 2H-Indol-2-one, 1,3-dihydro-5-(1-hydroxy-2-(1-piperazinyl)propyl)-3-methyl-, dihydrochloride (9CI) (CA INDEX NAME)				



● 2 HCl

L6 ANSWER 553 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 12 May 1994

GI For diagram(s), see printed CA Issue.

AB 4-, 5-, 6-, and 7-Cyanoindoles are converted in excellent yields into the corresponding formylindoles by sodium hypophosphite/nickel according to the method of Backeberg and Staskum (1961). Condensation of these formylindoles with nitromethane or nitroethane affords the related nitrovinylindoles, which are reduced to the title aminoalkylindoles by LiAlH₄. On the other hand, 5-chloroacetylindole is aminated by reaction with various secondary amines, and the amino ketones formed are reduced to the corresponding 5-(2-amino-1-hydroxyalkyl)indoles. Friedel-Crafts condensation of 1-acetyl-7-hydroxyindoline with ClCH₂COC₂Cl yields 1-acetyl-4-chloroacetyl-7-hydroxyindoline (I), which is transformed into indoline derivs. carrying a 2-amino-1-hydroxyethyl side-chain in position 4.

ACCESSION NUMBER: 1969:28749 HCAPLUS

DOCUMENT NUMBER: 70:28749

TITLE: Synthetic indole compounds. V. Syntheses of indoles with (2-aminoethyl)-, (2-aminopropyl)-, or alkanolamine side chains on the six-membered ring

AUTHOR(S): Troxler, Franz; Harnisch, A.; Bornmann, G.; Seemann, F.; Szabo, L.

CORPORATE SOURCE: Pharm. Chem. Forschungslab., Sandoz. A.-G., Basel, Switz.

SOURCE: Helvetica Chimica Acta (1968), 51(7), 1616-28

CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Journal

LANGUAGE: German


IT 20996-72-9P 20996-80-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 20996-72-9 HCAPLUS


CN Ketone, indol-5-yl (4-phenyl-1-piperazinyl)methyl (8CI) (CA INDEX NAME)



RN 20996-80-9 HCAPLUS

CN Indole-5-methanol, α-[(4-phenyl-1-piperazinyl)methyl]- (8CI) (CA

INDEX NAME)




L6 ANSWER 553 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

10511155amend

=> d ed abs ibib hitstr 500-510

L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Jan 1998
GI



AB Title compds. I [R1,R2 = H, Me, OH, HOCH2, N3, NO2, (un)substituted NH2,(un)substituted alkoxy, Cl, Br, (un)substituted alkylthio, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted aryl, (un)substituted heteroaryl; R3 = H, come), Y = OH, OAc; X = CO2Me, CH2OH] are prepared. I are useful for enhancing the function and/or survival of a trophic factor responsive cell. I inhibit interleukin-2 production and have immunosuppressive activity. Thus, I (R1, R2 = -CH2-2SMe, Y = OH, X = CO2Me, R3 = H) was prepared by reduction of the corresponding COCH2SMo substituted derivative. II showed 294% activity when tested at 300nM for spinal cord CHAT activity and 260% activity when tested at 250nM for basal forebrain CHAT activity as compared to the control.

ACCESSION NUMBER: 199811484 HCAPLUS

DOCUMENT NUMBER: 128:75237

TITLE: synthesis and neurotropic activity of selected derivatives of K-252a

INVENTOR(S): Hudkins, Robert L.; Mallamo, John P.; Hamano, Masami; Tanaka, Reiko; Murakata, Chikara

PATENT ASSIGNEE(S): Cephalon, Inc., USA; Kyowa Hakko Kogyo Co., Ltd.

SOURCE: PCT Int. Appl., 150 pp.

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9746565	A1	19971211	WO 1997-US9448	19970602
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200632-75-3 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrole[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-5,16-bis[(4-methyl-1-piperazinyl)acetyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 200632-95-7P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (synthesis and neurotropic activity of selected derivs. of K-252a)

RN 200632-95-7 HCAPLUS

9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrole[3,4-

L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA 2256633 AA 19971211 CA 1997-2256633 19970602
AU 9732253 A 19980105 AU 1997-32253 19970602
AU 716656 B2 20000302 NZ 1997-333018 19970602
EP 918777 A1 19980602 EP 1997-927906 19970602
EP 918777 B1 20020828 NZ 1998-5622 19981202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
BR 9711093 A 19980817 BR 1997-11093 19970602
CN 1226893 A 19980825 CH 1997-196985 19970602
NZ 333018 A 20000526 NZ 1997-333018 19970602
JP 2000511902 T2 20000912 JN 1998-500751 19970602
AT 222912 E 20020915 AT 1997-827906 19970602
PT 918777 T 20030131 PT 1997-827906 19970602
ES 2183184 T3 20030316 ES 1997-827906 19970602
RU 2205184 C2 20030527 RU 1999-100050 19970602
NO 9805622 A 19980202 NZ 1998-5622 19981202
NO 312464 B1 20020513 KR 1998-709862 19981203
KR 2000016289 A 20000325 KW 1998-10199 19981203
MX 9810189 A 20000531 MX 1998-10199 19981203
HK 1018703 A1 20030411 HK 1999-103763 19990831
NZ 504097 A 20050624 NZ 2000-504097 20000419
US 1996-657366 A 19960603
WO 1997-US9448 W 19970602

PRIORITY APPLN. INFO.: MARPAT 128:75237

OTHER SOURCE(S): IT 200632-74-2P 200632-75-3P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (synthesis and neurotropic activity of selected derivs. of K-252a)


RN 200632-74-2 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrole[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2-acetyl-10-(acetoxy)-2,3,9,10,11,12-hexahydro-9-methyl-5,16-bis[(4-methyl-1-piperazinyl)acetyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 200632-75-3 HCAPLUS
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrole[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2-acetyl-10-(acetoxy)-2,3,9,10,11,12-hexahydro-9-methyl-5,16-bis[(4-methyl-1-piperazinyl)propyl]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 24 Dec 1997
 AB Claimed are a method of locating one or more salts of a compound, the salts having a solubility in a cyclodextrin equal to or greater than a desired target solubility, comprising obtaining a series of salts of the compound, measuring the equilibrium solubility of each salt in the series in the cyclodextrin, and comparing each measured solubility with the target solubility. Ziprasidone mesylate was dissolved in a 300 mg/mL β -cyclodextrin sulfobutyl ether solution to make a concentration of 27.3 mg/mL. The solution was sterile filtered and filled into vials to give a product to be administered orally or by injections.
 ACCESSION NUMBER: 1997:601873 HCAPLUS
 DOCUMENT NUMBER: 128:66465
 TITLE: Method of selecting a salt for making an inclusion complex
 INVENTOR(S): Kim, Yesook
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 811386	A2	19971210	EP 1997-302821	19970424
EP 811386	A3	19990210		
EP 811386	B1	20040929		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
 AT 277641 E 20041015 AT 1997-302821 19970424
 PT 811386 T 20041231 PT 1997-302821 19970424
 ES 2224205 T3 20050301 ES 1997-302821 19970424
 US 200107862 A1 20010712 US 1997-850353 19970502
 CA 2204451 AA 19971107 CA 1997-2204451 19970505
 CA 2204451 C 20040629

PRIORITY APPLN. INFO.: US 1996-16866P P 19960507
 IT 122883-93-6DP, Ziprasidone hydrochloride, complexes with cyclodextrin ethers 185021-64-1DP, complexes with cyclodextrin ethers 199522-95-7DP, complexes with cyclodextrin ethers 199522-96-8DP, complexes with cyclodextrin ethers 199522-97-9DP, complexes with cyclodextrin ethers 199522-98-0DP, complexes with cyclodextrin ethers 199522-99-1DP, complexes with cyclodextrin ethers 199523-00-7DP, complexes with cyclodextrin ethers
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cyclodextrin inclusion complexes with drug salts)


RN 122883-93-6 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 1995021-64-1 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1
 CRN 146939-27-7
 CMF C21 H21 Cl N4 O S




CM 2
 CRN 75-75-2
 CMF C H4 O3 S

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 199522-95-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1
 CRN 146939-27-7
 CMF C21 H21 Cl N4 O S




CM 2
 CRN 104-15-4
 CMF C7 H8 O3 S




RN 199522-96-8 HCAPLUS
 CN 2-Naphthalenesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 146939-27-7

L6 ANSWER 501 OF 553 HCAPLUS . COPYRIGHT 2006 ACS on STN (Continued)




CM 2
 CRN 120-18-3
 CMF C10 H8 O3 S




RN 199522-97-9 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1
 CRN 146939-27-7
 CMF C21 H21 Cl N4 O S




CM 2

CRN 98-11-3
CMF C6 H6 O3 S

RN 199522-98-0 HCAPLUS
CN L-Aspartic acid, compd. with 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

CM 2


CRN 56-84-8
CMF C4 H7 N O4

Absolute stereochemistry. Rotation (+).



RN 199522-99-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

CM 2


CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 199523-00-7 HCAPLUS
CN Ethanesulfonic acid, compd. with 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 146939-27-7
CMF C21 H21 Cl N4 O S

CM 2

CRN 594-45-6
CMF C2 H6 O3 S

IT 146939-27-7, Ziprasidone
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclodextrin inclusion complexes with drug salts)



RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



IT 105021-64-1P 199522-99-1P 199523-00-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclodextrin inclusion complexes with drug salts)
RN 105021-64-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S


RN 109523-00-7 HCAPLUS

CN Ethanesulfonic acid, compd. with 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

CM 2


CRN 594-45-6
CMF C2 H6 O3 S

CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 109522-99-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

ED Entered STN: 27 Nov 1997

AB The compds. (I) are prepared by treatment of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one with MeSO3H. I are useful for the treatment of psychotic disorders (no data). Crystal data of I are also presented.

ACCESSION NUMBER: 1997-746048 HCAPLUS

DOCUMENT NUMBER: 128:22903

TITLE: Preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders

INVENTOR(S): Busch, Frank Robert; Rose, Carol Anne; Shine, Russell James

PATENT ASSIGNEE(S): Pfizer Inc., USA; Busch, Frank Robert; Rose, Carol Anne; Shine, Russell James

SOURCE: PCT Int. Appl., 27 pp.

DOCUMENT TYPE: Patent

CODEN: PIKKD2


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742191	A1	19971113	WO 1997-IB393	19970410
W: AI, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 491847	B	20020621	TW 1997-86104173	19970401
AU 9721747	A1	19971126	AU 1997-21747	19970410
AU 731267	B2	20010329		
CN 1216991	A	19990519	CN 1997-194244	19970410
CN 1091769	B	20021002		
EP 918772	A1	19990602	EP 1997-914520	19970410
EP 918772	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9709889	A	19990810	BR 1997-9889	19970410
JP 11509867	T2	19990831	JP 1997-539672	19970410
JP 3494659	B2	20040209		
NZ 508304	A	20010525	NZ 1997-508304	19970410
IL 126591	A1	20011125	IL 1997-126591	19970410
CZ 289215	B6	20011212	CZ 1998-3493	19970410
SK 282837	B6	20021203	SK 1998-1508	19970410
CA 2252898	C	20030409	CA 1997-2252898	19970410
CA 2252898	AA	19971113		
AT 278669	E	20041015	AT 1997-914520	19970410
PT 918772	T	20041231	PT 1997-914520	19970410
PL 198830	B1	20050131	PL 1997-329884	19970410
NZ 332218	A	20050225	NZ 1997-332218	19970410
ES 2229342	T3	20050416	ES 1997-914520	19970410
ZA 9703076	A	19981106	ZA 1997-3876	19970506
HR 970336	B1	20021231	HR 1997-970236	19970507
BG 63544	B1	20020430	BG 1998-102892	19981103
NO 9805194	A	19981106	NO 1998-5194	19981106
NO 312514	B1	20020521		
KR 2000010824	A	20000225	KR 1998-708960	19981106


L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 HK 1017892 A1 20030307 HK 1999-102953 19990712
 US 6245765 B1 20010612 US 1999-180455 19990830
 PRIORITY APPLN. INFO.: US 1996-16757P P 19960507
 IT 146939-27-7 NZ 1997-332218 A1 19970410
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)
 RN 146939-27-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



IT 185021-64-1 199191-69-0P 199191-70-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)
 RN 185021-64-1 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1
 CRN 146939-27-7
 CMF C21 H21 Cl N4 O S

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 199191-69-0 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, trihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
 CMF C21 H21 Cl N4 O S

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
 CRN 75-75-2
 CMF C H4 O3 S

RN 199191-70-3 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, dihydrate (9CI) (CA INDEX NAME)

CM 1
 CRN 146939-27-7
 CMF C21 H21 Cl N4 O S

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
 CMF C H4 O3 S




L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 27 Nov 1997
 AB The compds. (I) are prepared by treatment of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(H)-indol-2-one with MeSO₃H. I are useful for the treatment of psychotic disorders such as schizophrenia, migraine pain or anxiety (no data). Crystal data of I are also presented.
 ACCESSION NUMBER: 1997:746047 HCAPLUS
 DOCUMENT NUMBER: 126:22902
 TITLE: Preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(H)-indol-2-one for treatment of psychotic disorders
 INVENTOR(S): Busch, Frank R.; Rose, Carol A.
 PATENT ASSIGNEE(S): Pfizer Inc., USA; Busch, Frank R.; Rose, Carol A.
 SOURCE: PCT Int. Appl. 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742190	A1	19971113	WO 1997-IB306	19970326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9719368	A1	19971126	AU 1997-19368	19970326
AU 730856	B2	20010315		
EP 904273	A1	199900331	EP 1997-907237	19970326
EP 904273	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CN 1216990	A	19990519	CN 1997-194243	19970326
CN 1092658	B	20021016		
BR 9708932	A	19990803	BR 1997-8932	19970326
JP 11509865	T2	19990831	JP 1997-539668	19970326
JP 3102896	B2	20001023		
NZ 508303	A	20010727	NZ 1997-508303	19970326
IL 126590	A1	20011125	IL 1997-126590	19970326
CZ 289216	B6	20011212	CZ 1998-3494	19970326
CA 2252895	C	20020820	CA 1997-2252895	19970326
CA 2252895	AA	19971113		
SK 282674	B6	20021106	SK 1998-1505	19970326
AT 236902	E	20030415	AT 1997-907237	19970326
PT 904273	T	20030630	PT 1997-907237	19970326
ES 2192264	T3	20031001	ES 1997-907237	19970326
PL 188164	B1	20041231	PL 1997-329880	19970326
NZ 332219	A	20050225	NZ 1997-332219	19970326
TW 427989	B	20010401	TW 1997-86104175	19970401
AP 838	A	20000503	AP 1997-978	19970430
W: BW, GM, KE, MW, UG, ZM, ZW				
ZA 9703875	A	19981106	ZA 1997-3875	19970506

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 HR 970235 B1 20020831 HR 1997-970235 19970507
 BG 63601 B1 20020628 BG 1998-102893 19981103
 NO 9805193 A 19981106 NO 1998-5193 19981106
 NO 312513 B1 20020521 HK 1999-102956 19990712
 KR 2000010822 A 20000225 KR 1998-708958 19981106
 US 6110918 A 20000829 US 1999-180456 19990302
 HK 1017893 A1 20030307 HK 1999-16537P P 19990507
 NZ 1997-332219 A1 19970326 W 19970326

IT 146939-27-7P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(H)-indol-2-one for treatment of psychotic disorders)

RN 146939-27-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




IT 185021-64-1P 199191-69-OP 199191-70-3P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(H)-indol-2-one for treatment of psychotic disorders)

RN 185021-64-1 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1
 CRN 146939-27-7

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 199191-69-0 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, trihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
 CMF C21 H21 Cl N4 O S

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 199191-70-3 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
 CMF C21 H21 Cl N4 O S



CM 2


CRN 75-75-2
CMF C H4 O3 S

L6 ANSWER 504 OF 553 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
 BC 64474 B1 20050430 BG 1998-102894 19981103
 BG 64475 B2 20050430 BG 1998-108606 19981103
 US 6232304 B1 20010515 US 1998-147239 19981105
 NO 9805192 A 19981106 NO 1998-5192 19981106
 KR 2000010823 A 20000225 KR 1998-708959 19981106
 US 2001031756 A1 20011018 US 2001-850658 20010507
 US 6399777 B2 20020604

PRIORITY APPLN. INFO.: US 1996-19204P P 19960507
 WO 1997-IB321 W 19970401
 US 1998-147239 A3 19981105

OTHER SOURCE(S): MARPAT 128:39555
 IT 122883-93-6D, Ziprasidone hydrochloride, complexes with cyclodextrin derivs. 146939-27-7D, Ziprasidone, complexes with cyclodextrin derivs. 185021-64-1B, complexes with cyclodextrin derivs. 198522-95-7D, complexes with cyclodextrin derivs. 198522-96-8D, complexes with cyclodextrin derivs. 198522-97-9D, complexes with cyclodextrin derivs. 198522-98-0D, complexes with cyclodextrin derivs. 198522-99-1D, complexes with cyclodextrin derivs. 198523-00-7D, complexes with cyclodextrin derivs.
 RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

RN 122883-93-6 HCPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 146939-27-7 HCPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 504 OF 553 HCPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 27 Nov 1997
 AB Comprns. comprise a pharmaceutically acceptable salt of an aryl heterocyclic compound, such as ziprasidone, in a cyclodextrin. Preferred cyclodextrins are β -cyclodextrin sulfobutyl ether (SBECBD) and hydroxypropyl β -cyclodextrin (H β PCD). The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrin inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/mL When the complex is dissolved in Water at 40 % weight/volume A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate. A solution was prepared containing SBECBD and ziprasidone mesylate.


ACCESSION NUMBER: 1997:745974 HCPLUS
 DOCUMENT NUMBER: 128:39555
 TITLE: Inclusion complexes of aryl heterocyclic salts
 INVENTOR(S): Johnson, Kevin Charles; Kim, Yesook; Shanker, Ravi Mysore
 PATENT ASSIGNEE(S): Pfizer Inc., USA; Johnson, Kevin Charles; Kim, Yesook; Shanker, Ravi Mysore
 SOURCE: PCT Int. Appl., 23 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741896	A2	19971113	WO 1997-IB321	19970401
WO 9741896	A3	19980108		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TR, TT, UA, UG, US, UZ, VN, YU RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 514529	B	20021221	TW 1997-86103749	19970325
CA 2251912	AA	19971113	CA 1997-2251912	19970401
CA 2251912	C	20030603		
AU 9719372	A1	19971126	AU 1997-19372	19970401
AU 713711	B2	19991209		
EP 900088	A2	19990310	EP 1997-907246	19970401
EP 900088	B1	20040114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CN 1216922	A	19990519	CN 1997-194242	19970401
BR 9709213	A	19990810	BR 1997-9213	19970401
JP 11509866	T2	19990831	JP 1997-539669	19970401
JP 3579060	B2	20041020		
M2 332220	A	20000327	NZ 1997-332220	19970401
IL 126546	A1	20010128	IL 1997-126546	19970401
SK 28232	B6	20011008	SK 1998-1504	19970401
AT 257714	E	20040115	AT 1997-007246	19970401
PT 900088	T	20040430	PT 1997-007246	19970401
ES 2212089	T3	20040801	ES 1997-007246	19970401
PL 189324	B1	20050729	PL 1997-329928	19970401
ZA 9703874	A	19981106	ZA 1997-3874	19970506
HR 970237	B1	20020430	HR 1997-370237	19970507



RN 185021-64-1 HCPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)
 CM 1

CRN 146939-27-7
 CMF C21 H21 Cl N4 O S



CM 2
 CRN 75-75-2
 CMF C H4 O3 S


L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199522-95-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 146939-27-7
 CMF C21 H21 Cl N4 O S



CM 2


CRN 104-15-4
 CMF C7 H8 O3 S



RN 199522-96-8 HCAPLUS
 CN 2-Naphthalenesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)


L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 146939-27-7
 CMF C21 H21 Cl N4 O S



CM 2

CRN 120-18-3
 CMF C10 H8 O3 S




RN 199522-97-9 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 146939-27-7
 CMF C21 H21 Cl N4 O S

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 98-11-3
 CMF C6 H6 O3 S




RN 199522-98-0 HCAPLUS
 CN L-Aspartic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
 CMF C21 H21 Cl N4 O S


L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 56-84-8
 CMF C4 H7 N O4


Absolute stereochemistry. Rotation (+).



RN 199522-99-1 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 146939-27-7
 CMF C21 H21 Cl N4 O S



CM 2


CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 199523-00-7 HCAPLUS
CN Ethanesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

CM 2

CRN 594-45-6
CMF C2 H6 O3 S

ED Entered STN: 12 Nov 1997

AB The authors investigated the spectrum of drug binding of clin. available atypical antipsychotic drugs to multiple dopamine and 5-HT receptors and compared their binding spectrums with typical antipsychotic drugs. It appeared that atypical antipsychotic drugs are, in general, characterized by low D2 dopamine receptor affinity and relatively high affinities for various 5-HT receptors (SHT2A, SHT2C, SHT6, SHT7). The results suggest that since atypical antipsychotic drugs have relatively high affinity for a number of different receptors, ascribing their unique effects to any one receptor is likely to be unproductive.

ACCESSION NUMBER: 1997:712225 HCAPLUS

DOCUMENT NUMBER: 128:18607

TITLE: Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors

AUTHOR(S): Roth, Bryan L.; Meltzer, H. Y.; Khan, Naseem
CORPORATE SOURCE: Deps. Psychiatry, Neuroscis., Biochem., Case Western Res. Univ., Med. Sch., Cleveland, OH, 44106, USASOURCE: Advances in Pharmacology (San Diego) (1998), 42(Catecholamines), 482-485
CODEN: ADPHEL; ISSN: 1054-3589

PUBLISHER: Academic

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 146939-27-7, Ziprasidone

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(binding of typical and atypical antipsychotic drugs to multiple dopamine and 5-HT receptors)

RN 146939-27-7 HCAPLUS

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ED Entered STN: 13 Oct 1997

AB The present invention provides a method for treating pain using an atypical antipsychotic compound. Tablet formulations were given for compds. such as risperidone.

ACCESSION NUMBER: 1997:650272 HCAPLUS

DOCUMENT NUMBER: 127:298753

TITLE: Method for treating pain with an atypical antipsychotic compound

INVENTOR(S): Helton, David R.; Shannon, Haarlan E.; Womer, Daniel E.

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735584	A1	19971002	WO 1997-US4699	19970324
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RU: GH, KE, LS, MW, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, MU, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2250042	AA	19971002	CA 1997-2250042	19970324
AU 9725872	A1	19971017	AU 1997-25872	19970324
EP 906104	A1	19990407	EP 1997-917594	19970324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
JP 2000507544	T2	20000620	JP 1997-534520	19970324
US 6444665	B1	20020903	US 2000-498047	20000204
US 2003013689	A1	20030116	US 2002-224224	20020815
US 6936601	B2	20050830		

PRIORITY APPLN. INFO.: US 1996-14152P P 19960325
US 1997-823458 B1 19970324WO 1997-US4699 W 19970324
US 2000-498047 A3 20000204


IT 146939-27-7, Ziprasidone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treating pain with atypical antipsychotic compound)

RN 146939-27-7 HCAPLUS

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L6 ANSWER 507 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 17 Sep 1997
 AB A method is disclosed for use in assessing, in a subject suffering from a condition which may be treated with a 5-HT2 modulator, the likelihood whether the subject will be responsive or nonresponsive to treatment with a 5-HT2 modulator. The method comprises detecting the presence or absence of DNA encoding the Tyr452 and/or His452 alleles of the 5-HT2A gene in a biol. sample obtained from the subject. Genotyping for His452Tyr polymorphism was carried out using blood samples from individuals diagnosed as suffering from schizophrenia and being treated with clozapine. The individuals were also sep. assessed for responsiveness to clozapine treatment.

ACCESSION NUMBER: 1997:594839 HCAPLUS
 DOCUMENT NUMBER: 127:257506
 TITLE: Assessment of the responsiveness of individuals to modulators of the 5-HT2 receptors, especially the 5-HT2A receptor, by detection of receptor allele DNA
 INVENTOR(S): Kerwin, Robert; Collier, David; Roberts, Gareth Wyn
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK; Kerwin, Robert; Collier, David; Roberts, Gareth Wyn
 SOURCE: PCT Int. Appl., 18 pp.
 CODEN: PIAXAD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732037	A1	19970904	WO 1997-EP993	19970226
W: AL, AM, AT, AR, AZ, BA, BB, BG, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AR, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9710789	A1	19970916	AU 1997-16789	19970226
JP 20000506009	T2	20000523	JP 1997-530621	19970226
ZA 9701775	A	19971128	ZA 1997-1775	19970228
PRIORITY APPLN. INFO.:			GB 1996-4465	A 19960301
			WO 1997-EP993	W 19970226

IT 146939-27-7, Ziprasidone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (5-HT2 receptor modulator responsiveness assessment by detection of receptor allele DNA)
 RN 146939-27-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L6 ANSWER 508 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 17 Sep 1997
 AB A review with 24 refs. Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT2 and dopamine D2 receptors in vitro, with an 11-fold higher affinity for 5-HT2 than for D2 receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)]. The effects of ziprasidone in receptor binding studies reflected its in vitro pharmacol., with more potent effects against 5-HT2 receptor-than against D2 receptor-mediated behavior. Because ziprasidone inhibits serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine) reuptake, it may have anxiolytic and antidepressant effects. Data from phase II and III clin. trials have shown ziprasidone to be effective in reducing the pos. and neg. symptoms of, and depression associated with, schizophrenia, and in reducing anxiety in patients about to undergo dental surgery. Ziprasidone was generally well tolerated in phase II and III clin. trials, with somnolence and nausea being the most frequently reported adverse events in placebo-controlled studies. Motor disturbances, including EPS, were infrequently observed

ACCESSION NUMBER: 1997:593623 HCAPLUS
 DOCUMENT NUMBER: 127:242699
 TITLE: Ziprasidone
 AUTHOR(S): Davis, Rick; Markham, Anthony
 CORPORATE SOURCE: Adis International Limited, Auckland, N. Z.
 SOURCE: CNS Drugs (1997), 8(2), 153-159
 CODEN: CNDREF; ISSN: 1172-7047
 PUBLISHER: Adis
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 146939-27-7, Ziprasidone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ziprasidone for psychotic disorders)
 RN 146939-27-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L6 ANSWER 509 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 15 Sep 1997
 GI




I

AB Title compound (I) is prepared. Thus, ziprasidone was refluxed with PhCH₂SH in Me₂CO/H₂O to give 90.2% I. In radioligand binding studies for 5HT₂ receptors, I showed IC₅₀ = 0.35 nM.
 ACCESSION NUMBER: 1997:589196 HCAPLUS
 DOCUMENT NUMBER: 127:246126
 TITLE: Preparation of prodrugs of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.
 INVENTOR(S): Lambert, John Francis; Walinsky, Stanley Walter
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 790236	A1	19970820	EP 1997-200175	19970121
EP 790236	B1	20031119		
AT 254600	E	20031215	AT 1997-200175	19970121
PT 790236	T	20040430	PT 1997-200175	19970121
ES 2210450	T3	20040701	ES 1997-200175	19970121
CA 2197272	AA	19970814	CA 1997-219727	19970211
CA 2197272	C	20010123		
JP 09227516	A2	19970902	JP 1997-28993	19970213
JP 2911032	B2	19990623		

PRIORITY APPLN. INFO.: US 1996-11568P P 19960213
 IT 146939-27-7DP, Ziprasidone, prodrugs
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of prodrugs of 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one)
 RN 146939-27-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 509 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 195244-33-8 HCAPLUS
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of prodrugs of ziprasidone)
 RN 195244-33-8 HCAPLUS
 CN Piperazine, 1-[2-(6-chloro-2,3-dihydro-2-oxo-1H-indol-5-yl)ethyl]-4-(imino(2-mercaptophenyl)methyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 195244-32-7 HCAPLUS
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prodrg; preparation of prodrg of ziprasidone)
 RN 195244-32-7 HCAPLUS
 CN Piperazine, 1-[2-(6-chloro-2,3-dihydro-2-oxo-1H-indol-5-yl)ethyl]-4-(imino(2-mercaptophenyl)methyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 509 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 510 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 13 Aug 1997
 AB A method of assessing in a subject the likelihood whether said subject will be non-responsive or responsive to treatment with a drug the primary mode of action of which is via a process of altered synaptic activity, the method comprising detecting the presence or absence of DNA comprising the E2 allele of the ApoE gene, or of protein expressed by said DNA, in a biol. sample obtained from said subject. The method is exemplified with an atypical neuroleptic agent, i.e. clozapine.


ACCESSION NUMBER: 1997:511843 HCAPLUS
 DOCUMENT NUMBER: 127:117369
 TITLE: Method of predicting a subjects response to neuroleptic agents
 INVENTOR(S): Royston, Maureen Claire
 PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Royston, Maureen Claire
 SOURCE: PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721833	A1	19970619	WO 1996-EP5734	19961211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9713762	A1	19970703	AU 1997-13762	19961211
ZA 9610458	A	19980612	ZA 1996-10458	19961212

PRIORITY APPLN. INFO.: GB 1995-25481 A 19951213 WO 1996-EP5734 W 19961211
 IT 146939-27-7, Ziprasidone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug therapy of schizophrenia and detection of E2 allele of the ApoE gene for prediction of therapeutic outcome)
 RN 146939-27-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

10511155amend

L6 ANSWER 510 OF 553 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



10511155amend

=> log y			
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION	
FULL ESTIMATED COST	81.71	250.62	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION	
CA SUBSCRIBER PRICE	-11.25	-11.25	

STN INTERNATIONAL LOGOFF AT 12:07:49 ON 27 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:27:10 ON 27 APR 2006

FILE 'REGISTRY' ENTERED AT 12:27:16 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> Uploading C:\Program Files\Stnexp\Queries\10511155amend8.str



chain nodes :

10511155amend

```
10 11 12 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
10-11 11-12 12-13
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 18:CLASS

Generic attributes :

12:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
13:
Saturation : Unsaturated


Element Count :
Node 12: Limited

C,C4
N,N2
O,O0
S,S0

Node 13: Limited
C,C4-9

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 12:27:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 134667 TO ITERATE

10511155amend

1.5% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2671670 TO 2715010
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10511155amend9.str



chain nodes :

10 11 21

ring nodes :

1 2 3 4 5 6 7 8 9 15 16 17 18 19 20

chain bonds :

10-11 11-15 18-21

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20

exact/norm bonds :

2-7 3-9 7-8 8-9 11-15 15-16 15-20 16-17 17-18 18-19 18-21 19-20

exact bonds :

10-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

Generic attributes :

21:

Saturation : Unsaturated


Element Count :

Node 21: Limited
C,C4-9

L3 STRUCTURE UPLOADED

10511155amend

=> d 13
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 13
SAMPLE SEARCH INITIATED 12:29:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12894 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 251078 TO 264682
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s 13 full
FULL SEARCH INITIATED 12:29:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 257459 TO ITERATE

100.0% PROCESSED 257459 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.04

L5 21 SEA SSS FUL L3

=> fil hcaplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
168.26 168.47

FILE 'HCAPLUS' ENTERED AT 12:29:45 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15

L6 4 L5

=> d ed abs ibib hitstr 1-4

L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 07 May 2004
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention pertains to a method for producing 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one derivs. With general formula of I [wherein R1 = H or alkyl; n = 1-5] or pharmaceutically acceptable salts thereof. For example, the compound II was prepared in a multi-step synthesis comprising alkylation and hydrolysis starting from ziprasidone. I are useful as antipsychotics (no data).

ACCESSION NUMBER: 2004370931 HCAPLUS

DOCUMENT NUMBER: 140:375189

TITLE: Process for preparation of 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one derivatives

INVENTOR(S): Morris, Timothy; Colon-Cruz, Roberto

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037819	A1	20040506	WO 2003-IB4519	20031013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2500485	AA	20040506	CA 2003-2500485	20031013
AU 2003269331	A1	20040513	AU 2003-269331	20031013
EP 1556378	A1	20050727	EP 2003-751112	20031013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015516	A	20050823	BR 2003-15516	20031013
JP 2006050578	T2	20060216	JP 2004-546256	20031013
US 2004138232	A1	20040715	US 2003-689773	20031021
US 7019009	B2	20060328		
NO 2005002475	A	20050725	NO 2005-2475	20050523
PRIORITY APPLN. INFO.: US 2002-420843P	P	20021024		
WO 2003-IB4519	W	20031013		

OTHER SOURCE(S): CASREACT 140:375189; MARPAT 140:375189

IT 685567-41-3P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of [(benzisothiazolyl)piperazinyl]indole

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 24 Oct 2003
 GI



AB Title compds. I [R1 = H, A, SO2Ar; A = alkyl, alkoxalkyl; D-E = R2C=CR4, R2R3C-CR4R5; R2, R3, R4, R5 = H, A, cycloalkyl, etc.; X1 = (CHR7)g, (CHR7)h-Q-(CHR8)k; Q = O, NR6, etc.; R6 = H, A, cycloalkyl; R7, R8, R12 = definition as given for R2-R5; g = 1-6, h, k = 0-6; p = 0-3; E = H, A, cycloalkyl, etc.; X2 = (un)substituted alkylene; E and G together form (un)substituted mono or bicyclic heterocycle; X2 = definition as given for X1; Z = H, (un)substituted aromatic carbocycle and their pharmaceutically acceptable salts and formulations were prepared. For example, N-alkylation of 4-(4-fluorobenzyl)piperazine with methanesulfonic ester II, e.g., prepared from indole-3-carboxylic acid Me ester in 7-steps, afforded the dihydrochloride salt of indole-3-carbonitrile III after work-up. Compds. I are claimed useful as excitatory amino acid antagonists (no data provided) and as 5-HT reuptake inhibitors.

ACCESSION NUMBER: 2003-837073 HCAPLUS

DOCUMENT NUMBER: 139:337888

TITLE: Preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases

INVENTOR(S): Schadt, Oliver; Boettcher, Henning; Leibrock, Joachim; Schlemann, Kai; Heinrich, Timo; Hoelzemann, Guenter; Van Amsterdam, Christopher; Bartoszyk, Gerd; Seyfried, Christopher

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087066	A2	20031023	WO 2003-EP3806	20030411
WO 2003087066	A3	20040722		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 685567-41-3 HCAPLUS

CN Butanedioic acid, 5-[2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-(4-ethoxy-1,4-dioxobutyl)-1H-indol-2-yl ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-B

—OET

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

DE 10217006 A1 20031106 DE 2002-10217006 20020416

CA 2482655 AA 20031023 CA 2003-2482655 20030411

AU 2003224064 A1 20031027 AU 2003-224064 20030411

EP 1497279 A2 20050119 EP 2003-720455 20030411

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 2005153980 A1 20050714 US 2003-511155 20030411

JP 2005523310 T2 20050804 JP 2003-584042 20030411

PRIORITY APPLN. INFO.: DE 2002-10217006 A 20020416

WO 2003-EP3806 W 20030411

OTHER SOURCE(S): MARPAT 139:337888

IT 615569-38-5P 615569-39-6P 615569-40-9P

615569-41-0P 615569-42-1P 615569-44-3P

615569-46-5P 615569-47-6P 615569-54-5P

615569-60-3P 615569-62-5P 615569-63-6P

615569-66-9P 615569-71-6P 615569-72-7P


615569-73-8P 615569-77-2P

RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases)

RN 615569-38-5 HCAPLUS


CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-6-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 615569-39-6 HCAPLUS

CN 1H-Indole-3-carbonitrile, 5-[3-(4-(2-oxo-2H-1-benzopyran-6-yl)-1-


piperazinyl)propyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 615569-40-9 HCAPLUS
 CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-4-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-41-0 HCAPLUS
 CN 2-Benzofurancarboxamide, 5-[4-(3-(3-cyano-1H-indol-5-yl)propyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 615569-42-1 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1H-indol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 615569-44-3 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,1,3-benzothiadiazol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 615569-54-5 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 615569-60-3 HCAPLUS
 CN Acetamide, N-[6-(4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl)-2-oxo-2H-1-benzopyran-3-yl]- (9CI) (CA INDEX NAME)



RN 615569-62-5 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 615569-63-6 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 615569-66-9 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 615569-46-5 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(8-quinolinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 615569-47-6 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 615569-71-6 HCAPLUS
 CN Carbamic acid, [6-(4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl)-2-oxo-2H-1-benzopyran-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 615569-72-7 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[3-[4-(3-amino-2-oxo-2H-1-benzopyran-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 615569-73-8 HCAPLUS
 CN Carbamic acid, [6-(4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl)-2-oxo-2H-1-benzopyran-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 615569-77-2 HCAPLUS

L6 ANSWER 2 OF 4 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Benzofurancarboxamide, 5-[4-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl)- monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L6 ANSWER 3 OF 4 HCPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 06 Aug 2002
 AB Bifunctional mol., which possesses photoconductive and electrooptic properties in one mol., was synthesized as a new photorefractive material. Carbazole as a photoconductive moiety was covalently bound to thiophene derivative as an electrooptic chromophore via a flexible alkyl chain. The sample prepared from the mixture of bifunctional mol. (89 weight%), 2,5,7-trinitro-9-fluorenone (1 weight%) and ethylcarbazole (10 weight%) showed good photorefractive property. The 50 μm thick film showed the maximum diffraction efficiency of 65% at 70 V/μm, corresponding to a refractive index modulation (Δn) of ca. 4.5×10⁻³.
 ACCESSION NUMBER: 2002585265 HCPLUS
 DOCUMENT NUMBER: 138:00573
 TITLE: Synthesis and characterization of organic photorefractive glass
 AUTHOR(S): Chun, Hyunae; Kim, Nam-Jun; Joo, Won-Jae; Han, Jae Wook; Oh, Chang Ho; Kim, Nakjoong
 CORPORATE SOURCE: Center for Organic Photorefractive Materials, Department of Chemistry, Hanyang University, Seoul, 133-791, S. Korea
 SOURCE: Synthetic Metals (2002), 129(3), 281-283
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 481025-54-1F
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in preparation of photorefractive glass material)
 RN 481025-54-1 HCPLUS
 CN 2-Thiophenecarboxaldehyde, 5-[4-(6-(9-ethyl-9H-carbazol-3-yl)-6-methoxyhexyl)-1-piperazinyl] (9CI) (CA INDEX NAME)



IT 481025-59-6F
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (synthesis and characterization of organic photorefractive glass)
 RN 481025-59-6 HCPLUS
 CN Propanedinitrile, [(5-[4-(6-(9-ethyl-9H-carbazol-3-yl)-6-methoxyhexyl)-1-piperazinyl]-2-thienyl)methylene]- (9CI) (CA INDEX NAME)




L6 ANSWER 3 OF 4 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 HCPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 02 Mar 2001


GI



AB Title compds. [I; R1 = R(CH₂)_nZ1; R = (un)substituted naphthyl or heteroannelated Ph; R2R3 = atoms to complete a thiophene, furan, or (oxo)pyrrole ring; Z = bonds, O, (*α*,*α*'-alkyl)amino; Z1 = 1,4-cyclohexylene, piperidine-1,4- or -4,1-diyl, piperazine-1,4-diyl; n = 1-6] were prepared. Thus, 7-chlorofuro[2,3-*c*]pyridine was aminated by N-(2-naphthylmethyl)-4-piperidinemamine to give I (R1 = RCH₂NH₂, R = 2-naphthyl, R2R3 = OCH₂CH₂, Z1 = piperidine-4,1-diyl). Data for biol. activity of I were given.
 ACCESSION NUMBER: 2001152309 HCPLUS
 DOCUMENT NUMBER: 134:193415
 TITLE: Preparation of heteroannelated pyridines as 5-HT1A receptor ligands
 INVENTOR(S): Peglion, Jean-louis; Dessinges, Aimee; Poitevin, Christophe; Millan, Mark; Dekeyne, Anne
 PATENT ASSIGNEE(S): Adir Et Compagnie, Fr.; Les Laboratoires Servier
 SOURCE: Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1078928	A1	20010228	EP 2000-402359	20000825
EP 1078928	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2797874	A1	20010302	FR 1999-10834	19990827
FR 2797874	B1	20020329		
US 6399616	B1	20020604	US 2000-641777	20000818
JP 2001097978	A2	20010410	JP 2000-252191	20000823
JP 3602780	B2	20041215		
CA 2317053	AA	20010227	CA 2000-2317053	20000825
CA 2317053	A	20010228	ZA 2000-4411	20000825
BR 2000004411	A	20010307	CA 2000-124065	20000825
CN 1286255	A	20040515	AT 2000-402359	20000825
A2 266664	E	20040515	PT 2000-402359	20000825
PT 1078928	T	20040930	ES 2000-402359	20000825
ES 2220359	T3	20041216	NO 2000-4295	20000825
NO 2000004295	A	20010228	NO 2000-4295	20000828
NO 316651	B1	20040322		
BR 2000003648	A	20010403	BR 2000-3848	20000828
AU 765661	B2	20030925	AU 2000-53642	20000828
HK 1034250	A1	20050429	HK 2001-104815	20010711
US 2002161228	A1	20021031	US 2002-105171	20020325
US 6486171	B2	20021126		
PRIORITY APPLN. INFO.:			FR 1999-10834	A 19990827
			US 2000-641777	A3 20000818
OTHER SOURCE(S):	MARPAT 134:193415			
IT 327173-35-3P				

LC ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroannulated pyridines as 5-HT1A receptor ligands)
RN 327173-35-3 HCAPLUS
CN Furo[3,2-c]pyridine, 4-[4-(2-(1H-indol-5-yl)ethyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10511155amend

=> log y			
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION	
FULL ESTIMATED COST	22.97	191.44	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION	
CA SUBSCRIBER PRICE	-3.00	-3.00	

STN INTERNATIONAL LOGOFF AT 12:30:26 ON 27 APR 2006